BRAF and neoplasm: A 2022 randomised clinical trial comparing ipilimumab and nivolumab combination therapy versus monotherapy in untreated unresectable stage III or stage IV melanoma reported the longest median overall survival (OS) reported to date: 57% OS at 6.5 years with BRAF-mutant tumours and 46% OS at 6.5 years in BRAF-wild type tumours [2].